公司資料
GRI Bio 股價、新聞與催化劑
- 股票代碼:
- GRI
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.73 USD (+3.59%)
收盤價
最後更新: 2026年8月17日
3.56M USD
市值
股價為何變動
As of Aug 17, 2026, GRI closed up 3.59% at $1.73. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
所在地與產業分類
GRI is a U.S.-listed biotech entry with a small-cap development profile. It sits in biotechnology rather than medtech or services.
商業模式特徵
The business depended on early scientific progress, platform credibility, and access to capital. Investors historically watched whether the company could focus its pipeline and keep programs alive.
生技產業定位
GRI occupies the historical small-cap biotech bucket. It is the type of name where the market cared most about whether the science could survive the financing cycle.
未來催化劑
- GRI Bio's catalyst setup now looks most tied to cough/shortness of breath, Commission, and the rest of its current pipeline. What gives this more shape is "The growing body of Phase 2a clinical, translational and biomarker data continues to reinforce GRI-0621's differentiated therapeutic potential in idiopathic pulmonary fibrosis.... That setup makes the next update more important than the headline financials themselves. The partnership angle also matters here, especially around (6) the inability of the Company to identify, in-license or acquire additional technology.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。